Clade 1, with downregulation of pathways related to immune response identified in the analysis by ActivePathways (Interferon Gamma response, Interferon Alpha response, Inflammatory response, Allograft rejection, and TNF signalling via NF-KB), was enriched for tumours with early WGD (p = 0.04, Chi squared test). Here, NFKB1 is linked to neoplasm.